Human neutralising antibodies elicited by SARS-CoV-2 non-D614G variants offer cross-protection against the SARS-CoV-2 D614G variant.

Cheryl Yi-Pin LeeSiti Naqiah AmrunRhonda Sin-Ling CheeYun Shan GohTze-Minn MakSophie OctaviaNicholas Kim-Wah YeoZi Wei ChangMatthew Zirui TayAnthony Torres-RuestaGuillaume CarissimoChek-Meng PohSiew-Wai FongWang BeiSandy LeeBarnaby Edward YoungSeow-Yen TanYee-Sin LeoDavid C LyeRaymond Tp LinSebastien Maurer-StrohBernett LeeCheng-I WangLaurent ReniaLisa Fp Ng

Published in: Clinical & translational immunology (2021)

Cross-reactivity occurs at the functional level of the humoral response on both the S protein variants, which suggests that existing serological assays will be able to detect both D614 and G614 clades of SARS-CoV-2. More importantly, there should be negligible impact towards the efficacy of antibody-based therapies and vaccines that are currently being developed.

Keyphrases

sars cov
respiratory syndrome coronavirus
copy number
endothelial cells
immune response
high throughput
induced pluripotent stem cells
small molecule
binding protein
gene expression
protein protein
pluripotent stem cells